Improving Drug Abuse Treatment by Research and Training

通过研究和培训改善药物滥用治疗

• 批准号: 6361982
• 负责人: Herbert David Kleber
• 金额: $ 12.23万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6361982
• 关键词: Cannabis; buprenorphine; cocaine; detoxification; drug abuse chemotherapy; drug abuse therapy; drug withdrawal; heroin; human subject; human therapy evaluation; marijuana abuse; naltrexone; patient oriented research

DESCRIPTION: (Provided by Applicant) The overall aim of this K-05 proposal is to support and expand the applicant's work in developing and improving pharmacotherapy and psychotherapy for substance abuse as well as mentoring scientists embarking on such a career. The applicant has had a productive career in both areas, developing such programs first at Yale and currently at Columbia. During his eight years at Columbia the applicant has, in addition to these activities, served as Executive Vice President and Medical Director of CASA, a policy research center he and Joseph Califano founded in 1992. Receiving the K05 award would provide financial support for the candidate so that he could relinquish his CASA position with its administrative duties and policy research, and devote himself full time to biomedical research and training at the medical school. The applicant's current research has two major themes: 1) treating opioid withdrawal, 2) developing and improving medications and behavioral approaches for treating cocaine, heroin and marijuana dependence. Current funding for these areas is in hand for the first three years of this award. The applicant will direct a study comparing Anesthesia Rapid Opioid Detox (AROD) to Buprenorphine Rapid Opioid Detox to Clonidine Assisted Opioid Detox. The popularity of AROD has not been matched by evaluation of the technique, side effects and long term follow-up. This is the first controlled study to do so. In addition, the applicant will be PI at the Columbia site of a NIDA multi-site phase III trial of lofexidine, an alpha-adrenergic agonist with possible better efficacy than clonidine, and his Center will run an outpatient trial of a new Depot Naltrexone. Also focused on antagonist therapy is a Stage II Trial where he is Co-Investigator, testing a newly developed manualized psychotherapy for naltrexone-maintained individuals, which will also be the 1st study to test the usefulness of the new Depot Naltrexone in a clinical study. The Medication Development Research Center, where he is PI, focuses on targeting subgroups of addicts as well as development and/or utilization of models to improve testing potential medications. It includes human laboratory research on heroin, PET imaging, a large scale medication trial for cocaine, and testing potential medications for marijuana withdrawal and craving. In addition, the applicant plans to expand his time mentoring young scientists, including fellows on his training grant as well as young faculty. Additional time would also be spent in increasing collaborative research with other investigators at Columbia and developing new medication development projects.

描述：（申请人提供） 本K-05提案的总体目标是支持和扩展申请人的 致力于开发和改善药物治疗和心理治疗， 药物滥用以及指导科学家开始这样的职业生涯。的 申请人在这两个领域都有一个富有成效的职业生涯，发展这样的计划 最初在耶鲁大学，现在在哥伦比亚大学。在哥伦比亚的八年里， 申请人除了这些活动外，还担任过执行副总裁 他和约瑟夫是政策研究中心CASA的总裁兼医学主任 Califano成立于1992年。获得K 05奖将提供资金 支持候选人，使他能够放弃他的CASA的立场， 其行政职责和政策研究，并致力于全职 在医学院进行生物医学研究和培训。 申请人目前的研究有两大主题：1）治疗阿片类药物 戒断，2）开发和改善药物和行为方法 用于治疗可卡因、海洛因和大麻依赖。目前供资情况 这些领域是在这个奖项的头三年。申请人 将指导一项研究，比较麻醉快速阿片类药物排毒（AROD）， 丁丙诺啡快速阿片类药物排毒可乐定辅助阿片类药物排毒。的 AROD的流行程度与技术评价不匹配， 效果和长期随访。这是第一个这样做的对照研究。 此外，申请人将PI在哥伦比亚网站的NIDA多站点 洛非西定的III期试验，一种α-肾上腺素能激动剂， 疗效比可乐定，他的中心将运行一个新的门诊试验 纳洛酮仓库。还关注拮抗剂治疗的是II期试验， 他是合作研究者，测试一种新开发的手动心理治疗， 纳洛酮维持的个体，这也将是第一项测试 新的Depot Nalcadone在临床研究中的有用性。药物 发展研究中心，在那里他是PI，专注于针对亚组的 成瘾者以及开发和/或利用模型来改善测试 潜在的药物它包括对海洛因的人体实验室研究， 成像，可卡因的大规模药物试验，以及测试潜力 治疗大麻戒断和烟瘾的药物此外，申请人 计划扩大他的时间指导年轻科学家，包括研究员在他的 培训补助金以及年轻的教师。还将花费更多的时间， 增加与哥伦比亚其他研究人员的合作研究， 开发新药开发项目。